ライフサイエンスコーパス: B-cell activating factor

1 ifferentiation are substantially enhanced by B cell-activating factor.

2 family protein, which is inhibited by excess B cell-activating factor.

3 associated with liver inflammation and serum B cell-activating factor.

4 ly prolonged survival ex vivo independent of B cell activating factor and showed increased amounts of

5 Remarkably, both B cell-activating factor and CD40 ligand do not signific

6 eads to systemic inflammation with increased B cell-activating factor and IFN levels and induction of

7 for an abrogation of tolerance, no increased B cell-activating factor and IFN, and no IFN signature.

8 d B-cell counts, B-cell subset distribution, B cell-activating factor and immunoglobulin levels, and

9 d salivary glands and abnormal expression of B cell-activating factor and its receptors.

10 he formation of ectopic lymphoid structures (B-cell activating factor and B cell-attracting chemokine

11 ls are activated and primed for survival via B-cell activating factor and B-cell receptor-associated

12 The emergence of B-cell-activating factor and its related family members

13 incorporating the molecular adjuvants BAFF (B cell activating factor) and APRIL (a proliferation-ind

14 ers, as well as B-cell survival factor BAFF (B-cell activating factor) and antiapoptotic molecule Bcl

15 lammation, splenic plasma cells, circulating B cell activating factor, and intragraft transcripts for

16 or activator of NF-kB (RANK)-RANK ligand and B cell-activating factor-APRIL (a proliferation-inducing

17 Activation of the type I interferon/B cell-activating factor axis in SS has recently attract

18 ently to wild type in response to IgM, CD40, B cell-activating factor/B lymphocyte stimulator, CpG, a

19 At 2 years from transplantation, the B-cell activating factor/B-cell ratio was significantly

20 The B cell activating factor BAFF (BlyS/TALL-1/zTNF4) is a t

21 mbinant RABV-based vaccine expressing murine B cell activating factor (BAFF) (rRABV-mBAFF).

22 The cytokine B cell activating factor (BAFF) and its receptor, BAFF r

23 he tumor necrosis factor (TNF) family member B cell activating factor (BAFF) binds B cells and enhanc

24 B cell activating factor (BAFF) is a crucial survival fa

25 gulation of signals received through BCR and B cell activating factor (BAFF) receptor.

26 B cell activating factor (BAFF) signals through BAFF-R t

27 B cell activating factor (BAFF) stimulation of the BAFF

28 member 13B (B lymphocyte stimulator (BLyS), B cell activating factor (BAFF)) promotes primary B cell

29 B cell activating factor (BAFF), a ligand belonging to t

30 cells proliferate to the prosurvival factor B cell activating factor (BAFF).

31 We show here that B cell-activating factor (BAFF) activates this second pa

32 roteins and B cell tropic factors, including B cell-activating factor (BAFF) and a proliferation-indu

33 iated IgG-PB differentiation is dependent on B cell-activating factor (BAFF) and IL-10, whereas IgA-P

34 mpaired receptor editing and increased serum B cell-activating factor (BAFF) concentrations.

35 The B cell-activating factor (BAFF) is critical for B cell d

36 ents with cGVHD have significantly increased B cell-activating factor (BAFF) levels and that their B

37 e presence of alloantibodies and high plasma B cell-activating factor (BAFF) levels in patients with

38 show that Btk also couples the receptor for B cell-activating factor (BAFF) of the TNF family (BAFF-

39 independent survival signals provided by the B cell-activating factor (BAFF) receptor (BAFF-R).

40 am of both the B cell receptor (BCR) and the B cell-activating factor (BAFF) receptor.

41 ets, elevated IgG autoantibody reactivity to B cell-activating factor (BAFF) was associated with SLE

42 ey found autoantibodies directed against the B cell-activating factor (BAFF) were associated with gre

43 Expression of B cell-activating factor (BAFF), a critical B cell survi

44 cathelicidin, interleukin 1 (IL-1), IL-4 and B cell-activating factor (BAFF), after IgD crosslinking.

45 a proliferation-inducing ligand (APRIL) and B cell-activating factor (BAFF), tumor necrosis factor l

46 B cell dysfunctions, and one of these is the B cell-activating factor (BAFF).

47 ubsets, mirroring deficiency of the cytokine B cell-activating factor (BAFF).

48 is a novel splicing isoform of the regulator B cell-activating factor (BAFF, BLyS), a TNF family prot

49 The cytokine TNF family member B cell-activating factor (BAFF; also termed BLyS) is ess

50 ectively evaluated B-cell subpopulations and B-cell activating factor (BAFF) in 136 patients (46 BOS,

51 We measured serum B-cell activating factor (BAFF) in 46 cGVHD patients rec

52 B-cell activating factor (BAFF) is an important cytokine

53 B-cell activating factor (BAFF) single nucleotide polymo

54 B-cell activating factor (BAFF), a member of the TNF fam

55 pa B ligand (sRANKL), osteoprotegerin (OPG), B-cell activating factor (BAFF), and a proliferation-ind

56 G), a proliferation-inducing ligand (APRIL), B-cell activating factor (BAFF), interleukin (IL)-6, and

57 of APRIL (a proliferation-inducing ligand), B-cell activating factor (BAFF), tumor necrosis factor-a

58 SF13B, encoding the cytokine and drug target B-cell activating factor (BAFF), was associated with mul

59 tor receptor (BAFFR) expression and inhibits B-cell activating factor (BAFF)-induced B-cell survival

60 e stimulator (BLyS), also referred to as the B-cell activating factor (BAFF).

61 e genes included Tnfsf13b, which encodes the B-cell activating factor (BAFF).

62 B-cell-activating factor (BAFF) and its receptor BAFF-R

63 Sustained increase in B-cell-activating factor (BAFF) mRNA in the CNS and BAFF

64 As a result, mutant TWEAK associated with B-cell-activating factor (BAFF) protein and down-regulat

65 -142(-/-) B cells express elevated levels of B-cell-activating factor (BAFF) receptor (BAFF-R) and as

66 ivation, as well as a defect in BCR-mediated B-cell-activating factor (BAFF) receptor up-regulation a

67 Recent studies have underscored the role of B-cell-activating factor (BAFF), a member of the tumor n

68 a proliferation-inducing ligand (APRIL) and B-cell-activating factor (BAFF), whereas removal of term

69 apacity of a therapeutic mAb and blockade of B-cell-activating factor (BAFF)-BR3 B-cell survival.

70 The B-cell-activating factor (BAFF)-receptor (BAFF-R) is res

71 Elevated B-cell-activating factor (BAFF; TNFSF13B) levels have be

72 e mated with mice transgenic (Tg) for CD257 (B-cell activating factor, BAFF) developed CD5(+) B-cell

73 The B cell activating factor belonging to the tumor necrosis

74 B cell-activating factor belonging to the TNF family (BA

75 ly sensitive to the combination of IL-21 and B cell-activating factor belonging to the TNF family (BA

76 Constitutive overexpression of B cell-activating factor belonging to the TNF family (BA

77 3dg-binding CD21/CD19 costimulatory complex, B cell-activating factor belonging to the TNF family (BA

78 The TNF-related ligand, B cell-activating factor belonging to the TNF family (BA

79 B cell-activating factor belonging to the TNF family (BA

80 The TNF family cytokine B cell-activating factor belonging to the TNF family (BA

81 B cell-activating factor belonging to the TNF family (BA

82 to influence Mvarphi phenotype by mediating B cell-activating factor belonging to the TNF family (BA

83 pecificity, NF-kappaB activation through the B cell-activating factor belonging to the TNF family (BA

84 The effects of B cell-activating factor belonging to the TNF family (BA

85 B cell-activating factor belonging to the TNF family rec

86 y, superimposing genetic deficiency of BAFF (B cell-activating factor belonging to the TNF family) on

87 nd is resistant to the survival factor BAFF (B cell-activating factor belonging to the TNF family).

88 microenvironment, including signals from the B cell-activating factor belonging to the TNF family/BLy

89 BAFF (B cell-activating factor belonging to the tumor necrosis

90 studies have defined a crucial role for the B cell-activating factor belonging to TNF family (BAFF;

91 pril (a proliferation-inducing ligand)/BAFF (B cell-activating factor belonging to TNF), albumin, cho

92 2 cells released the B-cell survival factor, B-cell activating factor belonging to the TNF family (BA

93 B-cell activating factor belonging to the tumor necrosis

94 ults suggest that macrophage- and DC-derived B-cell-activating factor belonging to the TNF family (BA

95 ith the potent B-cell survival factor BAFF ('B-cell-activating factor belonging to the TNF family') p

96 B-cell survival and maturation factor BAFF (B-cell-activating factor belonging to the tumor necrosis

97 w discusses some of the pertinent aspects of B-cell-activating factor biology and considers how recen

98 involved in B lymphocyte development, BAFF (B cell activating factor, BlyS, TALL-1, CD257, TNFSF13B)

99 ection from spontaneous apoptosis induced by B cell-activating factors CD40L, TNF-alpha, and fibronec

100 Total airway IgE correlated with B-cell activating factor concentrations.

101 Serum levels of B-cell activating factor correlate with laboratory indic

102 s were maintained in a manner different from B-cell-activating-factor-dependent p52/RelB regulation.

103 its absence relieved B cells of the need for B cell activating factor for survival.

104 ession, and rendering B cells independent of B cell activating factor for survival.

105 family kinases, whereas it is independent of B-cell activating factor, IFN, and Toll-like receptor si

106 By neutralizing B cell-activating factor in vivo, we found an arrest in

107 ction after B-cell receptor stimulation, and B-cell activating factor-induced nuclear factor kappaB2/

108 fic cytokines (insulin-like growth factor-1, B-cell activating factor, interleukin-6, interleukin-10)

109 (-) and CD21(low) B cells and a reduction in B cell-activating factor levels.

110 s against double-stranded DNA, and increased B cell-activating factor levels.

111 ere reduced despite slightly increased serum B cell-activating factor levels.

112 (eg, zoledronic acid, anti-DKK-1 MoAb, anti-B-cell activating factor MoAb and bortezomib, Btk inhibi

113 Mice overexpressing B cell activating factor of the TNF family (BAFF) develo

114 B cell activating factor of the TNF family (BAFF), also

115 BAFF (B cell activating factor of the TNF family, also known a

116 B cell activating factor of the tumor necrosis factor fa

117 e mice results in the elevated production of B cell-activating factor of the TNF family ((BAFF) also

118 d the functions of the TNF family cytokines, B cell-activating factor of the TNF family (BAFF) and a

119 non-Hodgkin's lymphoma (NHL) B cells express B cell-activating factor of the TNF family (BAFF) and a

120 The TNF family members B cell-activating factor of the TNF family (BAFF) and it

121 a proliferation-inducing ligand (APRIL) and B cell-activating factor of the TNF family (BAFF) but th

122 ther augmentation in mitogenic responses and B cell-activating factor of the TNF family (BAFF) recept

123 Herein we demonstrate that B cell-activating factor of the TNF family (BAFF), a B c

124 volved in the immunopathology of RA, such as B cell-activating factor of the TNF family (BAFF), ICOS

125 n requires additional signals from BCR and a B cell-activating factor of the TNF family (BAFF), produ

126 that they stained with mAb specific for the B cell-activating factor of the TNF family (BAFF; also c

127 is also associated with increased levels of B cell-activating factor of the TNF family (BAFF; also k

128 B cell-activating factor of the TNF family and a prolife

129 In addition, LMP1 induces B cells to express B cell-activating factor of the TNF family and a prolife

130 DC-produced survival factors such as B cell-activating factor of the TNF family and a prolife

131 The B cell-activating factor of the TNF family receptor (BAF

132 function are completely independent of BAFF (B cell-activating factor of the TNF family) or APRIL (a

133 IgG and IgA production was enhanced by BAFF (B cell-activating factor of the TNF family), an innate m

134 -4 or IL-10, whereas Ab secretion requires a B cell-activating factor of the TNF family.

135 nate and adaptive immune systems through the B cell-activating factor of the TNF family.

136 We examined expression of B cell-activating factor of the tumor necrosis factor (T

137 The ASC survival factors B cell-activating factor of the tumor necrosis factor (T

138 cell life depends critically on the cytokine B cell-activating factor of the tumor necrosis factor fa

139 rs of the B cell-activating TNF superfamily (B cell-activating factor of TNF family (BAFF) and a prol

140 we show that NF-kappaB activation induced by B cell-activating factor of tumor necrosis factor family

141 s express BR3, the specific receptor for the B cell-activating factor of tumor necrosis factor family

142 B cell-activating factor of tumor necrosis factor family

143 )) for APRIL and the closely related ligand, B-cell activating factor of the TNF family (BAFF), bind

144 The B-cell activating factor of the TNF family (BAFF), nucle

145 aling from the B-cell receptor (BCR) and the B-cell activating factor of the TNF family receptor (BAF

146 n of the effects of rituximab (anti-CD20) on B-cell-activating factor of the tumor necrosis factor fa

147 ein expression of NIK is steadily induced by B cell-activating factor or CD40 ligand, two major physi

148 lls (IgG(+)); and (5) both TNFRSF17 mRNA and B cell-activating factor protein were up-regulated.

149 Signaling from the BCR and B cell activating factor receptor (BAFF-R or BR3) differ

150 w here that PTP1B negatively regulates CD40, B cell activating factor receptor (BAFF-R), and TLR4 sig

151 eptors sensitive to trophic factors, such as B cell-activating factor receptor (BAFF-R or BR3) during

152 quires cooperative signaling through BCR and B cell-activating factor receptor 3 (BR3).

153 ne production, proliferation of T cells, and B cell-activating factor receptor expression on B cells.

154 e Ptpn22, we show evidence for enhanced BCR, B cell-activating factor receptor, and CD40 coreceptor p

155 induced IL-15 production in B cells through B cell-activating factor receptor, whereas IL-15, a pote

156 sing functional itBreg cells in a CD40L- and B cell-activating factor receptor-dependent manner.

157 Rather, high CD45 expression reduces B-cell activating factor receptor (BAFFR) expression and

158 (dpi) was more dominantly controlled by the B-cell-activating factor receptor (BAFF-R), a gene that

159 nalling of B-cell activation molecules CD69, B-cell-activating factor receptor, and transmembrane act

160 High-level soluble B-cell activating factor (sBAFF) was observed in kidney

161 The recruited neutrophils secreted a B cell-activating factor that highly accelerated plasma

162 The approval of anti-B cell activating factor therapy and an increasing body

163 Fo cells responded to AgR stimulation and to B cell activating factor, they displayed decreased survi

164 rated mediators, matrix metalloproteinase-9, B-cell activating factor, transforming growth factor-bet

165 of CLL or normal B cells with CD40-ligand or B-cell-activating factor upregulated miR-155 and enhance

166 ant CXCL13 was up-regulated >1,000-fold, and B cell-activating factor was also detected.

167 chemokines (CXCL13, CCL19, CCL21, CCL1, and B-cell-activating factor) was increased in pancreatic an